A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy

Journal of Hepatology

Volumn 61, Issue 3, 2014, Pages 508-514

  Burton, James R ^a   O'Leary, Jacqueline G ^b   Verna, Elizabeth C ^c   Saxena, Varun ^d   Dodge, Jennifer L ^d   Stravitz, Richard T ^e   Levitsky, Joshua ^f   Trotter, James F ^b   Everson, Gregory T ^a   Brown, Robert S ^c   Terrault, Norah A ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiviral therapy; Boceprevir; Interferon; Ribavirin; Telaprevir

Indexed keywords

BOCEPREVIR; HEMOGLOBIN; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; LEUKOPENIA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84906303033     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.04.037     Document Type: Article

References (26)

1. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
2. N. Yilmaz, M.L. Shiffman, R.K. Stravitz, R.K. Sterling, V.A. Luketic, and A.J. Sanyal et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation Liver Transpl 13 2007 975 983
3. J.A. Carrion, F. Torres, G. Crespo, R. Miquel, J.C. Garcia-Valdecasas, and M. Navasa et al. Liver stiffness identified two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation Hepatology 51 2010 23 34
4. M. Berenguer, M. Prieto, J.M. Rayon, J. Mora, M. Pastor, and V. Ortiz et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation Hepatology 32 2000 852 858
5. C.S. Wang, H.H. Ko, E.M. Yoshida, C.A. Marra, and K. Ricardson Interferon-baed combination antiviral therapy for hepatitis C virus after liver transplantation: a review an quantitative analysis Am J Transpl 6 2006 1586 1599
6. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
7. E. Xirouchakis, C. Triantos, P. Manousou, A. Sigalas, V. Calvaruso, and A. Corbani et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies J Viral Hepat 15 2008 699 709
8. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
9. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
10. S. Zeuzem, P. Andrenone, S. Pol, E. Laawitz, M. Diego, and S. Roberts et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
11. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
12. V. Garg, R. van Heeswijk, J.E. Lee, K. Alves, P. Nadkarni, and X. Luo Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus Hepatology 54 2011 20 27
13. E. Hulskotte, S. Gupta, F. Xuan, M. van Zutven, E. O'mara, and H.P. Fent et al. Pharmacokinetic interaction between hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers Hepatology 56 2012 1622 1630
14. A. Coilly, B. Roche, J.C. Duclos-Vallee, and D. Samuel Management of HCV transplant patients with triple therapy Liver Int 34 2014 46 52
15. J.G. O'leary, G.J. McKenna, G.B. Klintmalm, and G.L. Davis Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients Liver Transpl 19 2013 463 465
16. M. Berenguer, A. Palau, A. Fernandez, S. Benlloch, V. Aguilera, and M. Prieto et al. Efficacy, predictors or response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C Liver Transpl 12 2006 1067 1076
17. J.J. Kiser, J.R. Burton, P.L. Anderson, and G.T. Everson Review and management of drug interactions with boceprevir and telaprevir Hepatology 55 2012 1620 1628
18. R.J. Firpi, C. Soldevila-Pico, G.G. Morelli, R. Cabrera, C. Levy, and V.C. Clark et al. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study Dig Dis Sci 55 2010 196 203
19. R. Rabie, K. Mumtaz, and E.L. Renner Efficacy of antiviral therapy for hepatitis c after liver transplantation with cyclosporine and tacrolimus: a systematic review and meta-analysis Liver Transpl 19 2013 46 48
20. A. Coilly, B. Roche, J. Dumortier, V. Leroy, D. Botta-Fridlund, and S. Radenne et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation, a multicenter experience J Hepatol 60 2014 78 86
21. S. Pungpapong, B.A. Aqel, L. Koning, J.L. Murphy, T.M. Henry, and K.L. Rylan et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation Liver Transpl 19 2013 690 700
22. M. Giusto, M. Rodriguez, L. Navarro, A. Rubin, V. Aguilera, and F. San-Juan et al. Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin Liver Transpl 17 2011 1318 1327
23. Y. Hodo, K. Tsuji, E. Mizukoshi, T. Yamashita, A. Sakai, and Y. Nakamoto et al. Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C Transpl Int 19 2006 170 171
24. S. Mauss, D. Hueppe, and U. Alshuth Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir Hepatology 59 2014 46 48
25. M. Charlton, E. Seaberg, R. Wiesner, J. Everhart, R. Zetterman, and J. Lake et al. Predictors of patient and graft survival following liver transplantation for hepatitis C Hepatology 28 1998 823 830
26. M. Prieto, M. Berenguer, J.M. Rayon, J. Cordoba, L. Arguello, and D. Carrasco et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256